

AMENDMENTS TO THE CLAIMS

Please update the claims in accordance with the claim listing found below.

CLAIMS:

We claim:

1-11. (Canceled)

12. (Currently amended) An ~~oligonucleotide of the~~ interfering ribonucleic acid (iRNA) type comprising from ~~40~~ 15 to 60 nucleotides, which ~~hybridizes specifically~~ are complementary to a corresponding portion of the sequence SEQ ID No. 21 and which inhibits the expression of OB-RGRP.

13. (Original) The oligonucleotide as claimed in claim 12, which is a double-stranded RNA.

14. (Previously presented) A vector expressing an oligonucleotide as claimed in one of claims 12 or 13.

15. (Previously presented) A cell containing a vector as claimed in either of claims 13 and 14.

16. (Previously presented) A medicinal product containing an oligonucleotide, as claimed in one of claims 12 or 13.

17. (Previously presented) A pharmaceutical composition containing a pharmacologically active amount of an oligonucleotide, as claimed in one of claims 12 or 13 and pharmaceutically acceptable excipients.

18-44. (Canceled)

45. (Previously presented) A medicinal product containing a vector as claimed in claim 14.

46. (Previously presented) A medicinal product containing a cell as claimed in claim 15.

47. (Previously presented) A pharmaceutical composition containing a pharmacologically active amount of a vector as claimed in claim 14 and pharmaceutically acceptable excipients.
48. (Previously presented) A pharmaceutical composition containing a pharmacologically active amount of a cell as claimed in claim 15 and pharmaceutically acceptable excipients.